Analysts have been eager to weigh in on the Healthcare sector with new ratings on Heron Therapeutics (HRTX) and LivaNova (LIVN).
Heron Therapeutics (HRTX)
Needham analyst Serge Belanger maintained a Buy rating on Heron Therapeutics today and set a price target of $28.00. The company’s shares closed last Wednesday at $19.29.
According to TipRanks.com, Belanger is a 4-star analyst with an average return of 15.1% and a 54.4% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, KalVista Pharmaceuticals, and Zynerba Pharmaceuticals.
Currently, the analyst consensus on Heron Therapeutics is a Strong Buy with an average price target of $28.75, which is a 59.4% upside from current levels. In a report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $28.00 price target.
See today’s analyst top recommended stocks >>
LivaNova (LIVN)
Needham analyst Michael Matson maintained a Hold rating on LivaNova today. The company’s shares closed last Wednesday at $73.99, close to its 52-week high of $77.29.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 17.5% and a 71.8% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.
Currently, the analyst consensus on LivaNova is a Moderate Buy with an average price target of $73.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
